Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252757 | 0.92 | PLK4 (0.37) | NPC1RAB9AKIF11LIMK1LMNA | |
| SCHEMBL10249355 | 0.90 | NPC1 (0.42) | NPC1RAB9AKIF11LTA4HGRIN1 | |
| SCHEMBL13152238 | 0.90 | LMNA (0.46) | NPC1RAB9AKIF11LIMK1HASPIN | |
| SCHEMBL13151765 | 0.90 | BRD4 (0.35) | NPC1RAB9ALMNAMAPK1PGR | |
| SCHEMBL10249318 | 0.90 | PLK4 (0.40) | NPC1RAB9ALIMK1ARPGR | |
| SCHEMBL10097596 | 0.89 | CACNA1F (0.43) | NPC1RAB9ALTA4HKCNH2LIMK1 | |
| SCHEMBL13152607 | 0.88 | SGK1 (0.39) | GRIK1GRIK2 | |
| SCHEMBL10097376 | 0.88 | AR (0.41) | NPC1RAB9ALIMK1LMNAAR | |
| SCHEMBL10249433 | 0.87 | SGK1 (0.36) | NPC1RAB9ALIMK1ARGRIK1 | |
| SCHEMBL13152559 | 0.87 | GRIK2 (0.46) | NPC1RAB9AKIF11LIMK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | NPC1 297/4885RAB9A 3975/4885KIF11 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.